Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma

Evasive mechanisms triggered by the tyrosine kinase inhibitor sorafenib reduce its efficacy in hepatocellular carcinoma (HCC) treatment. Drug-resistant cancer cells frequently exhibit sphingolipid dysregulation, reducing chemotherapeutic cytotoxicity via the induction of ceramide-degrading enzymes....

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Stefanovic, Milica, Tutusaus, Anna, Martinez-Nieto, Guillermo A., Bárcena, Cristina, de Gregorio, Estefania, Moutinho, Catia, Barbero-Camps, Elisabet, Villanueva, Alberto, Colell, Anna, Marí, Montserrat, García-Ruiz, Carmen, Fernandez-Checa, Jose C., Morales, Albert
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4884990/
https://ncbi.nlm.nih.gov/pubmed/26811497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6982
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы